Exchange: NASDAQ·Updated 01:22 PM EDT
AUPH logo

AUPHAurinia Pharmaceuticals Inc

$16.58
$0.35
(2.16%)
Today
EarningsJul 30
Mkt Cap$2.09B
Vol513,744.00
News
all
press releases
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150...
Business Wire
News Placeholder
More News
News Placeholder
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
News Placeholder
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Zacks
News Placeholder
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Zacks
News Placeholder
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Zacks
News Placeholder
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Key Points814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share...
Nasdaq News: Markets
News Placeholder
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Zacks
News Placeholder
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation). This new...
Business Wire
News Placeholder
Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy
read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.